We partner with business builders creating long-term transformational economic and societal value.
January 30, 2023
Deka Biosciences ("Deka"), a biotech company focused on developing novel cytokine therapies to treat cancer and inflammatory diseases, today announced that the U.S. Food and Drug Administration (FDA) has completed its review of the investigational new drug (IND) application for DK210 (EGFR) and concluded that Deka may proceed with a Phase 1 clinical trial in the United States.
Read MoreNovember 3, 2022
Contract Development and Manufacturing Organization (CDMO) Wheeler Bio and CRB – a leading global provider of sustainable engineering, architectural, construction and consulting services to the life sciences industry – today announced the start of construction on a GMP drug substance facility that will support innovators seeking agile, small batch manufacturing services for their clinical trial materials (CTM).
Read More